Back to results
US 11,446,374 B2Granted
Modified RSV F proteins and methods of their use
AssigneeNovavax, Inc.
InventorsPeter M. Pushko, Yingyun Wu, Michael J. Massare, Ye Liu, Gale Smith, Bin Zhou
Life of this patent
Estimating the term…
Abstract
The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.
Claims12
A vaccine composition comprising
- (i) a viral glycoprotein consisting of an RSV F glycoprotein comprising an inactivated primary furin cleavage site, and a wild-type secondary furin cleavage site having an amino acid sequence of RARR (SEQ ID NO:
- 23), wherein the primary cleavage site is at amino acids 131 to 136 and the secondary cleavage site is at amino acids 106 to 109, numbered according to SEQ ID NO:2;
- wherein the primary furin cleavage site is inactivated by amino acid substitution of one or more amino acids of arginine 133, arginine 135 and arginine 136;
- wherein the RSV F glycoprotein lacks an N-terminal signal peptide;
- wherein the RSV F glycoprotein is cleaved into F1 and F2 subunits which are disulfide linked, and wherein a p27 protein is connected to the F1 subunit via an amide bond;
- wherein the only viral glycoprotein in the composition is the RSV F glycoprotein;
- and
- (ii) an adjuvant.
5 more elements
Dependencies are inferred from the claim text.